Akebia Therapeutics/$AKBA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Akebia Therapeutics
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
- Ticker
- $AKBA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 194
- Headquarters
- Waltham, United States
- Website
- www.akebia.com
AKBA Metrics
BasicAdvanced
$111M
-
-$0.17
0.23
-
Price and volume
Market cap
$111M
Beta
0.23
52-week high
$2.07
52-week low
$0.36
Average daily volume
8.5M
Financial strength
Current ratio
1.36
Quick ratio
1.205
Long term debt to equity
7.707
Total debt to equity
10.151
Interest coverage (TTM)
-1.28%
Profitability
EBITDA (TTM)
-18.757
Gross margin (TTM)
81.05%
Net profit margin (TTM)
-22.60%
Operating margin (TTM)
-10.19%
Effective tax rate (TTM)
-3.20%
Revenue per employee (TTM)
$1,020,000
Management effectiveness
Return on assets (TTM)
-3.56%
Return on equity (TTM)
-143.83%
Valuation
Price to revenue (TTM)
0.549
Price to book
5.47
Price to tangible book (TTM)
-2.88
Price to free cash flow (TTM)
93.74
Free cash flow yield (TTM)
1.07%
Free cash flow per share (TTM)
0.004
Growth
Revenue change (TTM)
-12.38%
Earnings per share change (TTM)
161.87%
3-year revenue growth (CAGR)
0.51%
3-year earnings per share growth (CAGR)
-19.03%
10-year earnings per share growth (CAGR)
-25.67%
What the Analysts think about AKBA
Analyst ratings (Buy, Hold, Sell) for Akebia Therapeutics stock.
Analyst projections of the future price of Akebia Therapeutics stock.
AKBA Financial Performance
Revenues and expenses
AKBA Earnings Performance
Company profitability
Upcoming events
No upcoming events
AKBA News
AllArticlesVideos
Funds containing AKBA
Fund name | Fund size | $AKBA weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.00% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.